Overview

This is a single-arm, open-label, dose escalation, phase I study, aiming to evaluate the safety and efficacy of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific Chimeric Antigen Receptor (CAR) T-cells in patient with relapsed or refractory diffuse B cell lymphoma.

Eligibility

Inclusion Criteria:

1. The subject or her/his legally guardian(s) must sign the informed consent form approved by the Institutional Ethics Committee (IEC) prior to any screening procedures;
2. Subjects aged 18 years or older with relapsed or refractory DLBCL (primary mediastinal large B-cell lymphoma and transformed follicular lymphoma included), of which refractory is defined as:

Have no response to the recent treatment including:

• The best response to the treatment regimen is progressive disease (PD) ,or
• stable disease (SD) which maintained less than 6 months after the last treatment, or
• not suitable for autologous hematopoietic stem cell transplantation (ASCT), or ASCT refractory, including:
• progressive disease after ASCT or relapse within 12 months (relapse must be confirmed by biopsy), or
• If remedial treatment is given after ASCT, the subject must have no response or relapse after the last treatment. 3. Subjects who have previously received 2 lines treatment, and at least including:
• Anti-CD20 monoclonal antibody(rituximab), unless the CD20 negative;
• A chemotherapy regimen containing anthracyclines;
• The DLBCL patients who transformed from follicular lymphoma must have previously received chemotherapy for follicular lymphoma and have developed chemotherapy-refractory diseases after transform to DLBCL. 4. Confirmation for either CD19 or CD20 positivity using immunohistochemistry or flow cytometry; 5. According to the initial evaluation, staging and response assessment of Hodgkin's and non-Hodgkin's lymphoma -the Lugano Classification (2014), there is at least one measurable lesion at baseline; 6. Life expectancy 12 weeks; 7. Eastern Cooperative Oncology Group (ECOG) performance status that is either 0 or 1 at screening; 8. Adequate organ function:

Renal function defined as:

• A serum creatinine of 1.5 Upper Limit of Normal (ULN), or;
• Estimated Glomerular Filtration Rate (eGFR) 60 ml/min/1.73m2

Liver function defined as:

• ALT 5 Upper Limit of Normal (ULN) for age, and;
• Total bilirubin 2.0 mg/dl with the exception of patients with Gilbert-Meulengracht syndrome; patients with Gilbert-Meulengracht syndrome may be included if their total bilirubin is 3.0 ULN and direct bilirubin 1.5 ULN.

Must have a minimum level of pulmonary reserve defined as Grade 1 dyspnea and blood oxygen saturation > 91% on room air;

9. Hemodynamically stable and Left Ventricle Ejection Fraction (LVEF) 45% confirmed by echocardiogram or Multigated Radionuclide Angiography (MUGA);

10. Adequate bone marrow reserve without transfusions defined as:

• Absolute neutrophil count (ANC) >110^9 /L
• Absolute lymphocyte count (ALC) 0.310^9 /L
• Platelets 5010^9 /L;
• Hemoglobin > 8.0 g/dl; 11. Must have an apheresis product of non-mobilized cells or peripheral blood harvested cells accepted for manufacturing 12. Subjects who use the following drugs should meet the following criteria:
• Steroids: Therapeutic doses of steroids must be stopped 2 weeks prior to A-02 infusion. However, the following physiological replacement doses of steroids are allowed: < 6 - 12 mg/m^2/day hydrocortisone or equivalent;
• Immunosuppression: Any immunosuppressive medication must be stopped 4 weeks prior to sign the informed consent form;
• Anti-proliferative therapy other than pretreatment chemotherapy within 2 weeks of A-02 infusion;
• CD20 antibody-related treatment must be discontinued within 4 weeks of A-02 infusion or 5 half-lives (whichever is longer);
• CNS disease prophylaxis must be stopped > 1 week prior to A-02 infusion (e.g. intrathecal methotrexate); 13. The investigator judged that the subject recovered from the toxicity of the previous anti-tumor treatment to grade 1 or below (except for special grade 2 or below toxicity that cannot be recovered in a short period of time, such as hair loss), suitable for pretreatment. Chemotherapy and treatment of CAR-T cells; 14. Women of child-bearing potential and all male subjects must agree to use highly effective methods of contraception for at least 12 months following A-02 infusion and until CAR-T cells are no longer present by PCR on two consecutive tests.

Exclusion Criteria:

1. Prior treatment with any cell therapy before signing the informed consent form, including CAR-T therapy;
2. Subjects with detectable cerebrospinal fluid malignant cells or brain metastases, or with a history of central nervous system (CNS) lymphoma or primary CNS lymphoma;
3. Subjects with testicular invasion, including those who have had testicular resection;
4. Subjects with current or previous history of central nervous system disease, such as seizures, cerebral ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease involving the central nervous system;
5. Subjects who have previously received allogeneic hematopoietic stem cell transplantation (HSCT); or suitable and consenting to Autologous hematopoietic stem cell transplantation (ASCT);
6. Chemotherapy other than lymphodepleting chemotherapy within 2 weeks of A-02 infusion;
7. Patients on oral anticoagulation therapy within 1 week of A-02 infusion;
8. Prior radiation therapy within 2 weeks of A-02 infusion;
9. Investigational medicinal product within the last 30 days prior to sign the informed consent form;
10. Subjects with active hepatitis Bdefined as hepatitis B surface antigen positive, or hepatitis B core antibody positive with hepatitis B virus DNA detection value > 1000 copies/mlor hepatitis C (HCV RNA positive)
11. Subjects positive for HIV antibody or treponema pallidum antibody;
12. Uncontrolled acute life threatening bacterial, viral or fungal infection (e.g. blood culture positive 72 hours prior to A-02 infusion)
13. Unstable angina and/or myocardial infarction within 6 months prior to sign the informed consent form;
14. Previous or concurrent malignancy with the following exceptions:
    • Adequately treated basal cell or squamous cell carcinoma (adequate wound healing is required prior to sign the informed consent form);
    • In situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 3 years prior to sign the informed consent form;
    • A primary malignancy which has been completely resected and in complete remission for 5 years;
15. Pregnant or nursing women (women of childbearing age were tested positive for pregnancy during screening period);
16. Cardiac arrhythmia not controlled with medical management;
17. Subjects with active neurological auto immune or inflammatory disorders (e.g. Guillain Barre Syndrome, Amyotrophic Lateral Sclerosis);
18. Other conditions that the investigator thinks he/she should not be included in this clinical trial, such as poor compliance.